Skip to main content
. 2018 Dec 7;58(4):650–655. doi: 10.1093/rheumatology/key357

Table 1.

Baseline demographics and time to cancer occurrence for the anti-TIF1-Ab-positive and negative cohorts

Total cohort (n = 263) Anti-TIF1-Ab positive (n = 55) Anti-TIF1-Ab negative (n = 208)
Female, n (%) 181 (69) 44 (80) 137 (66)*
Smokers, n (%) 82 (31) 17 (31) 65 (31)
Follow-up, years, median (IQR) 10 (7–17) 10 (6–15) 12 (8–18)
Age of DM onset, years, median (IQR) No subsequent cancer diagnosis 47 (35–60) 45 (34–58) 47 (37–59)
Subsequent cancer diagnosis 59 (48–66) 59 (50–65) 58 (49–69)
Age at cancer diagnosis, years, median (IQR) 61 (52–68) 60 (52–67) 62 (52–70)
Time from DM to cancer onset, years, median (IQR) 4.3 (1.5–9.4) 1.4 (0.7–2.5) 5.0 (2.5–10.4)*
Cancer cases during total follow-up period, n (%) 53 (20) 21 (38) 32 (15)*
Cases classified as CAMa, n (%) 42 (16) 21 (38) 21 (10)*
Patients with cancer within 3 years preceding DM onset, n (%) 16 (6) 7 (13) 9 (4)*
Patients with cancer within 3 years following DM onset, n (%) 26 (10) 14 (26) 12 (6)*

aCAM: cancer occurring within 3 years either side of DM onset.

Variables of the anti-TIF1-Ab-positive cohort were compared against those of the anti-TIF1-Ab-negative cohort. *P < 0.01 (categorical variables were compared with the chi-squared test, continuous variables were compared using the Mann–Whitney U test). Anti-TIF1-Ab: anti-transcriptional intermediary factor 1 antibody.